Search Results - "Molina, André"
-
1
Confocal reflectance microscopy in basal cell carcinoma associated with nevus sebaceous: case report
Published in Anais brasileiros de dermatología (01-11-2024)Get full text
Journal Article -
2
Relapse in dermatofibrosarcoma protuberans: A histological and molecular analysis
Published in Journal of surgical oncology (01-04-2018)“…Background Dermatofibrosarcoma protuberans (DFSP) is a rare low grade tumor with a locally aggressive behavior and low metastatic potential. Objectives To…”
Get full text
Journal Article -
3
Artificial dermis (Matriderm®) followed by skin graft as an option in dermatofibrosarcoma protuberans with complete circumferential and peripheral deep margin assessment
Published in International wound journal (01-10-2015)“…Dermatofibrosarcoma protuberans (DFSP) is a locally invasive neoplasia with a pattern of infiltrative growth that leads to extended resections. To avoid…”
Get full text
Journal Article -
4
Popliteal sentinel lymph node involvement in melanoma patients
Published in Journal of surgical oncology (01-08-2015)“…Background Sentinel lymph nodes (SLN) in popliteal basins are rare, and there is controversy in literature regarding their origin, management, and outcomes…”
Get full text
Journal Article -
5
Metastatic area ratio can help predict nonsentinel node positivity in melanoma patients
Published in Melanoma research (01-02-2016)“…Several studies suggest that melanoma patients with a positive sentinel node biopsy (SNB) can avoid having complete nodal dissection on the basis of…”
Get full text
Journal Article -
6
Evaluation of Melanoma Features and Their Relationship with Nodal Disease: The Importance of the Pathological Report
Published in Tumori (01-09-2015)“…Background The pathological features of melanoma biopsies can provide significant prognostic information that can help the surgeon evaluate the risk of nodal…”
Get full text
Journal Article -
7
Dermatofibrosarcoma protuberans of the vulva: margins assessment and reconstructive options - a report of two cases
Published in World journal of surgical oncology (29-12-2014)“…Dermatofibrosarcoma Protuberans (DFSP) of the vulva is rare and oncologic surgery with free margins may lead to severe functional damage, requiring…”
Get full text
Journal Article -
8
Role of Annexin A1 Secreted by Neutrophils in Melanoma Metastasis
Published in Cells (Basel, Switzerland) (27-01-2023)“…Annexin A1 (AnxA1) is highly secreted by neutrophils and binds to formyl peptide receptors (FPRs) to trigger anti-inflammatory effects and efferocytosis. AnxA1…”
Get full text
Journal Article -
9
Local therapy in advanced melanoma after immune checkpoint inhibitors aiming to achieve complete response
Published in Journal of cancer research and therapeutics (01-07-2023)“…Background and Objectives: New scenarios for local therapy have arisen after starting immune checkpoint inhibitors (ICIs) to treat advanced melanoma (AM). The…”
Get full text
Journal Article -
10
Brazilian Society of Surgical Oncology recommendations on Merkel cell carcinoma surgical treatment
Published in Journal of surgical oncology (01-09-2024)“…Background Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer with poor 5‐year survival rates. Surgery and radiation are the current first‐line…”
Get full text
Journal Article -
11
Metabolic investigation of patients with urolithiasis in a specific region
Published in International Brazilian journal of urology (01-06-2003)“…To assess the prevalence of the main metabolic alterations found in patients with recent diagnosis of urolithiasis in the West region of Parana state, Brazil…”
Get full text
Journal Article -
12
Isolated limb infusion with hyperthermia and chemotherapy for advanced limb malignancy: factors influencing toxicity
Published in ANZ journal of surgery (01-09-2014)“…Background The isolated limb infusion (ILI) technique is a simpler and less invasive alternative to isolated limb perfusion, which allows regional…”
Get full text
Journal Article -
13
A Lightweight Unsupervised Learning Architecture to Enhance User Behavior Anomaly Detection
Published in 2022 IEEE Latin-American Conference on Communications (LATINCOM) (30-11-2022)“…In recent years, user behavior anomaly detection has been gaining attention in cybersecurity. A crucial challenge that has been discussed in the literature is…”
Get full text
Conference Proceeding -
14
Isolated limb perfusion with hyperthermia and chemotherapy: predictive factors for regional toxicity
Published in Clinics (São Paulo, Brazil) (01-01-2012)“…Isolated limb perfusion combined with melphalan is an accepted treatment for obtaining locoregional control in advanced melanoma of the extremities and other…”
Get full text
Journal Article -
15
Analysis of neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma using the SWOG S1801 event-free survival definition
Published in Journal of clinical oncology (01-06-2024)“…e21563 Background: Perioperative pembrolizumab to advanced melanoma, as shown SWOG S1801 trial, was associated with a longer event-free survival (EFS) than…”
Get full text
Journal Article -
16
Combined EORTC FDG-PET/CT and RECIST 1.1 response criteria and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma
Published in Journal of clinical oncology (01-06-2024)“…9590 Background: Accurate identification of pathological response to neoadjuvant therapy for clinical stage III melanoma before surgery may allow us to better…”
Get full text
Journal Article -
17
FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma
Published in Journal of clinical oncology (01-06-2023)“…9585 Background: Neoadjuvant immunotherapy with nivolumab 3mg/kg and ipilimumab 1 mg/kg (N3+I1) for two cycles for clinical stage III melanoma have shown rates…”
Get full text
Journal Article -
18
FDG-PET/CT response and outcome of neoadjuvant immunotherapy for clinical stage III melanoma
Published in Journal of clinical oncology (20-05-2021)“…Abstract only e21569 Background: Neoadjuvant immunotherapy with nivolumab 3mg/kg and ipilimumab 1mg/kg for two cycles(N3+I1) or anti-PD1 for 3-8 weeks for…”
Get full text
Journal Article -
19
-
20